4/18
02:10 am
ganx
Hansa Biopharma interim report January-March 2024 [Yahoo! Finance]
Low
Report
Hansa Biopharma interim report January-March 2024 [Yahoo! Finance]
4/10
11:19 am
ganx
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX) [Yahoo! Finance]
Low
Report
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX) [Yahoo! Finance]
4/8
09:25 am
ganx
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
Medium
Report
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
4/1
09:29 am
ganx
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
4/1
09:25 am
ganx
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
Medium
Report
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
4/1
08:08 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
3/27
08:09 am
ganx
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Medium
Report
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
3/26
08:12 am
ganx
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update [Yahoo! Finance]
Low
Report
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update [Yahoo! Finance]
3/26
08:00 am
ganx
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
Low
Report
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
3/15
02:30 pm
ganx
Gain Therapeutics to Present at Public Ventures Discovery Day
Low
Report
Gain Therapeutics to Present at Public Ventures Discovery Day
3/5
09:57 am
ganx
EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease [Yahoo! Finance]
Medium
Report
EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease [Yahoo! Finance]
3/5
08:10 am
ganx
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease [Yahoo! Finance]
Medium
Report
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease [Yahoo! Finance]
3/5
08:00 am
ganx
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
Medium
Report
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
2/27
02:13 pm
ganx
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease [Yahoo! Finance]
Low
Report
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease [Yahoo! Finance]
2/27
02:00 pm
ganx
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Low
Report
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
2/22
09:35 am
ganx
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer [Yahoo! Finance]
2/14
12:45 pm
ganx
Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight [Yahoo! Finance]
Low
Report
Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight [Yahoo! Finance]
2/14
12:29 pm
ganx
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
Medium
Report
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
2/6
09:56 am
ganx
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Low
Report
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
2/6
08:13 am
ganx
Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease [Yahoo! Finance]
Low
Report
Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease [Yahoo! Finance]
2/6
08:00 am
ganx
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Medium
Report
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
1/31
08:12 am
ganx
Gain Therapeutics' CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update [Yahoo! Finance]
Neutral
Report
Gain Therapeutics' CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update [Yahoo! Finance]
1/31
08:00 am
ganx
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
Neutral
Report
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
1/24
01:56 pm
ganx
Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know [Yahoo! Finance]